Multiple Myeloma · line 2 · Daratumumab + Carfilzomib + Dexamethasone (DKd / D-Kd / Isa-Kd analog), 28-day cycles
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-DKD |
| ID | IND-MM-2L-DKD |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-MM |
| Sources | SRC-ESMO-MM-2023 SRC-NCCN-MM-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L for r/r MM after 1L bortezomib-based progression, particularly lenalidomide- refractory. Isa-Kd is interchangeable equivalent if isatuximab accessible. Both daratumumab + carfilzomib are major UA access barriers.
Used By
Algorithms
ALGO-MM-2L- ALGO-MM-2L